Bufotenin (5-hydroxy-N,N-dimethyltryptamine, 5-HO-DMT) is a tryptamine alkaloid found in the skin glands and venom of toads in the Bufo genus (now largely reclassified as Rhinella and Incilius), in the seeds of South American trees Anadenanthera peregrina (yopo) and Anadenanthera colubrina (cebil/vilca), and in trace amounts in certain Amanita mushroom species. It is also an endogenous compound in humans, detectable in urine and implicated -- controversially -- in some hypotheses about the biochemistry of psychosis .
What makes bufotenin fascinating -- and frustrating for researchers -- is the long-running debate over whether it is genuinely psychoactive when administered to humans. Structurally, it is the 5-hydroxylated analog of DMT, differing by a single hydroxyl group. This modification makes the molecule considerably more polar, and the prevailing pharmacological consensus for decades was that bufotenincannot effectively cross the blood-brain barrier in sufficient quantities to produce central psychedelic effects. Early intravenous studies by Fabing and Hawkins (1956) at the Ohio State Penitentiary reported intense cardiovascular distress -- facial flushing, chest tightness, profound anxiety -- but ambiguous psychedelic effects, leading many researchers to dismiss it as peripherally active only .
However, this conclusion has been challenged. The ethnobotanist Jonathan Ott demonstrated in 2001 that intranasal bufotenin at doses of 40+ mg produced clear "visionary effects" without the cardiovascular distress reported in injection studies, suggesting that route of administration -- not inherent inability to cross the BBB -- may be the critical variable . Indigenous peoples of the Caribbean, Venezuela, and the southern Amazon have used Anadenanthera seed preparations (yopo,cohoba,vilca) via nasal insufflation for millennia, lending ethnographic support to its psychoactivity by this route.
References
McBride MC. Bufotenine: toward an understanding of possible psychoactive mechanisms. Journal of Psychoactive Drugs. 2000;32(3):321-331. Torres CM, Repke DB. Anadenanthera: Visionary Plant of Ancient South America. Haworth Press. 2006. Fabing HD, Hawkins JR. Intravenous bufotenine injection in the human being. Science. 1956;123(3203):886-887. Ott J. Pharmahuasca, anahuasca and voacangahuasca: ritual and recreational use of tryptamines. MAPS Bulletin. 2001;11(1):26-32.
Safety at a Glance
High Risk- It is strongly recommended that one use harm reduction practices when using this drug.
- Dangerous Interactions
- Toxicity: The toxicity and long-term health effects of recreational bufotenin do not seem to have been studied in any scientifi...
- Overdose risk: Fatal overdose from Bufotenin alone, at doses within the typical recreational range, is extremely...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
smoked
Duration
smoked
Total: 15 min – 1.5 hrsHow It Feels
The onset of bufotenin is rapid and physically imposing. Within minutes of administration — whether smoked, insufflated, or absorbed through mucous membranes — a powerful rush of blood pressure and facial flushing takes hold. The face becomes hot and red, the head pounds with a throbbing pressure, and there is a sense of constriction in the chest and throat that can be genuinely alarming. Nausea is common and sometimes severe. The physical discomfort is the dominant feature of the early experience, and it arrives with an urgency that can make the first few minutes deeply unpleasant.
As the cardiovascular effects stabilize — typically within five to fifteen minutes — the psychoactive dimensions begin to emerge from behind the wall of physical discomfort. Visual changes are the most prominent: colors become intensely vivid, taking on a luminous, almost phosphorescent quality. Geometric patterns may appear on surfaces, though they tend to be simpler and less structured than those produced by other tryptamines. There is a strange quality of visual depth — objects may appear closer or farther than they actually are, and the perception of three-dimensional space becomes fluid and unreliable. Closed-eye visuals can be vivid: bright, swirling fields of color and light.
The peak, which arrives quickly and lasts roughly fifteen to forty minutes, combines visual intensity with a peculiar, often disorienting headspace. Thought patterns become unusual and difficult to track — not the flowing ideation of classical psychedelics, but something more fragmentary and strange. There may be moments of profound clarity or beauty interspersed with periods of confusion and discomfort. The body remains a demanding presence throughout: the facial flushing, the pounding headache, and the nausea compete for attention with whatever perceptual gifts the compound is offering.
The experience is short — typically resolving within sixty to ninety minutes — and the comedown is marked more by physical relief than by psychological afterglow. As the pressure in the head subsides and the nausea fades, there is a grateful sense of returning to normal. A mild visual enhancement and a sense of perceptual freshness may linger for an hour or two. The overall character of bufotenin is that of a powerful but physically demanding tryptamine whose gifts arrive wrapped in a considerable amount of discomfort, asking the user to pay a somatic toll for whatever psychedelic insight it provides.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(11)
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily heaviness— Perception of bodily heaviness is the subjective feeling that one's body has become dramatically hea...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Skin flushing— Visible reddening of the skin due to vasodilation, most prominent on the face and chest, commonly ca...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(7)
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
Cognitive(18)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Autonomous voice communication— Autonomous voice communication is the experience of hearing and engaging in conversation with one or...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Pharmacology
Bufotenin's pharmacology is dominated by a central paradox: it binds to the same receptors as powerfully psychoactive tryptamines like DMT and psilocin, yet its ability to produce central psychedelic effects in humans has been debated for over half a century .
Receptor Binding
At the molecular level, bufotenin shows clear activity at 5-HT2A and5-HT2C serotonin receptors -- the same targets through which LSD, psilocin, and DMT produce their hallucinogenic effects. Computational receptor modeling confirms that bufotenin can bind to and activate these receptors with meaningful affinity, and in vitro functional assays demonstrate agonist activity comparable to that of known hallucinogens . It also binds to5-HT1A receptors and has been shown to interact with5-HT4 receptors in human cardiac tissue, where it produces positive inotropic and chronotropic effects -- a finding relevant to its cardiovascular side effect profile .
The Blood-Brain Barrier Problem
The core of the psychoactivity debate is bufotenin's poor penetration of the blood-brain barrier (BBB). The 5-hydroxyl group on the indole ring makes the molecule significantly more hydrophilic than DMT or 5-MeO-DMT, and in vitro BBB models suggest limited passive diffusion across the endothelium . This does not necessarily mean zero CNS penetration -- active transport mechanisms, areas of BBB permeability (circumventricular organs), and high-dose saturation of peripheral metabolism could all allow some central access. The question is whether enough bufotenin reaches brain tissue to activate 5-HT2A receptors at psychoactive concentrations.
Peripheral Cardiovascular Effects
What is beyond dispute is bufotenin's potent peripheral activity. The cardiovascular effects observed in human studies -- facial flushing (due to vasodilation in some vascular beds), hypertension, tachycardia, and nystagmus -- are mediated by peripheral serotonin receptors and are dose-dependent . These effects can be severe at higher intravenous doses and likely confounded early assessments of psychoactivity, since subjects in the Fabing and Hawkins studies were experiencing significant cardiovascular distress simultaneously with any potential central effects .
Resolving the Debate
The emerging consensus, informed by Ott's intranasal studies and by the millennia-long ethnographic record of Anadenanthera snuff use, is that bufotenin is centrally psychoactive when administered by routes that achieve sufficient CNS exposure -- particularly intranasal insufflation, which may bypass some first-pass metabolism and achieve higher peak plasma concentrations. The earlier negative findings likely reflected inadequate dosing, inappropriate route selection, and the confounding distress of peripheral effects rather than genuine absence of central activity .
References
McBride MC. Bufotenine: toward an understanding of possible psychoactive mechanisms. Journal of Psychoactive Drugs. 2000;32(3):321-331. Neumann J, et al. Cardiovascular effects of bufotenin on human 5-HT4 serotonin receptors in cardiac preparations. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023;396:2869-2878. Fabing HD, Hawkins JR. Intravenous bufotenine injection in the human being. Science. 1956;123(3203):886-887. Ott J. Pharmahuasca, anahuasca and voacangahuasca: ritual and recreational use of tryptamines. MAPS Bulletin. 2001;11(1):26-32.
Detection Methods
Urine Detection
Bufotenin is not targeted by standard immunoassay-based urine drug screens. 5-MeO-substituted tryptamines are metabolized primarily through hepatic pathways involving CYP2D6 and monoamine oxidase enzymes, producing demethylated and hydroxylated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect these metabolites in urine for approximately 24 to 48 hours after ingestion, though the detection window varies with dose and individual metabolic rate. The short duration of action of most 5-MeO tryptamines correlates with a relatively brief detection window.
Blood and Serum Detection
Blood detection windows for Bufotenin are short, typically 2 to 8 hours after administration depending on the route. Smoked or insufflated routes produce rapid peak concentrations followed by swift clearance, while oral administration (particularly with MAO inhibition) extends both the effect and detection windows. LC-MS/MS is required for reliable blood quantification at the low nanogram-per-milliliter concentrations typical of 5-MeO tryptamines.
Standard Drug Panel Inclusion
Bufotenin is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. 5-MeO tryptamines do not cross-react with any standard immunoassay panel targets. There is no reliable cross-reactivity with amphetamine, opiate, or any other standard immunoassay. Detection requires a specific request for tryptamine testing at a laboratory with novel psychoactive substance capabilities.
Confirmatory Methods
Definitive identification of Bufotenin requires LC-MS/MS or GC-MS analysis with compound-specific reference standards. Some forensic toxicology laboratories include 5-MeO-DMT in their expanded tryptamine panels, but coverage of other 5-MeO variants is less common. Bufotenin (5-HO-DMT), a metabolite of 5-MeO-DMT, may also be targeted. Quantitative analysis requires validated methods, as the structural similarity among 5-MeO tryptamines can complicate chromatographic separation without optimized conditions.
Reagent Testing (Harm Reduction)
The Ehrlich reagent produces a purple to violet reaction with Bufotenin, confirming the presence of an indole ring characteristic of all tryptamines. This is the primary field identification tool and should always be the first test performed. The Hofmann reagent provides a confirmatory blue reaction. The Marquis reagent typically shows no reaction or a faint yellow to brown discoloration with 5-MeO tryptamines. Because 5-MeO tryptamines can be significantly more potent by weight than 4-substituted analogs, reagent testing alone is not sufficient for safe use. Quantitative analysis and accurate dosing are critically important for this subclass.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
The history of Bufotenin is intertwined with the broader story of psychedelic research, which has oscillated between periods of intense scientific interest and strict prohibition.
Like many psychedelic compounds, Bufotenin was either synthesized in a laboratory setting or identified as a naturally occurring psychoactive substance through ethnobotanical research. The mid-20th century saw an explosion of interest in psychedelic compounds, with researchers exploring their potential applications in psychotherapy, creativity enhancement, and the study of consciousness.
The political and cultural backlash of the late 1960s and early 1970s led to the criminalization of most psychedelic substances, effectively halting legitimate research for decades. The resurgence of psychedelic research beginning in the 2000s — often called the "psychedelic renaissance" — has renewed scientific interest in this class of compounds, with clinical trials exploring applications in treatment-resistant depression, PTSD, end-of-life anxiety, and addiction.
Bufotenin exists within this broader pharmacological and cultural context, with its specific history shaped by its date of discovery, legal status, availability, and unique pharmacological profile.
Harm Reduction
It is strongly recommended that one use harm reduction practices when using this drug. -not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.almost immediately after ingestion. After that,12 hours to be back at baseline (in the absence of further consumption). Bufotenin does not have a cross-tolerance with other psychedelics, meaning that after the consumption of bufotenin psychedelics will not have a reduced effect.
- Dangerous Interactions
Deaths from bufotenin are rare but, as a powerful monoamine reuptake inhibitor (MRI), injury can occur when excessive doses are taken or when taken with drugs such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine. This has resulted in well documented deaths that are easily avoidable and could have been otherwise prevented.
Germany: Bufotenin is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of Bufotenin are punishable as an incitement to place it on the market.
Switzerland: Bufotenin is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United Kingdom: Bufotenin is a Class A drug.
United States: Bufotenin is a Schedule I substance.
Responsible use
Psychoactive substance index
Psychedelics
Bufotenin (Wikipedia)
Bufotenin (Erowid Vault)
Bufotenin (TiHKAL / Is
Toxicity & Safety
The toxicity and long-term health effects of recreational bufotenin do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because bufotenin is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried bufotenin suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
Bufotenin is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of bufotenin is built almost immediately after ingestion. After that, it takes about 1 hour for the tolerance to be reduced to half and 2 hours to be back at baseline (in the absence of further consumption). Bufotenin does not have a cross-tolerance with other psychedelics, meaning that after the consumption of bufotenin psychedelics will not have a reduced effect.
Dangerous Interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of Bufotenin. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals. Deaths from bufotenin are rare but, as a powerful monoamine reuptake inhibitor (MRI), injury can occur when excessive doses are taken or when taken with drugs such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine. This has resulted in well documented deaths that are easily avoidable and could have been otherwise prevented.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from Bufotenin alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 1 hour |
| Zero | 2 hours |
Cross-tolerances
Legal Status
Germany: Bufotenin is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of Bufotenin are punishable as an incitement to place it on the market.
Switzerland: Bufotenin is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United Kingdom: Bufotenin is a Class A drug.
United States: Bufotenin is a Schedule I substance.
Responsible use
Psychoactive substance index
Psychedelics
Bufotenin (Wikipedia)
Bufotenin (Erowid Vault)
Bufotenin (TiHKAL / Isomer Design)
Bufotenin (DrugBank)
Experience Reports (1)
Tips (4)
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of Bufotenin for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
Clear your schedule for the full duration of Bufotenin plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid Bufotenin and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Start with a low dose of Bufotenin if it is your first time. You can always take more next time but you cannot take less once ingested. The difference between a comfortable and an overwhelming experience can be surprisingly small.
See Also
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: Bufotenin
PubChem compound page for Bufotenin (CID: 10257)
pubchem - Bufotenin - TripSit Factsheet
TripSit factsheet for Bufotenin
tripsit - Bufotenin - Wikipedia
Wikipedia article on Bufotenin
wikipedia